Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
KCNMB1 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q16558 |
|---|---|
| Clone Names | 100525210 |
| Gene ID | 3779 |
|---|---|
| Other Names | Calcium-activated potassium channel subunit beta-1, BK channel subunit beta-1, BKbeta, BKbeta1, Hbeta1, Calcium-activated potassium channel, subfamily M subunit beta-1, Calcium-activated potassium channel subunit beta, Charybdotoxin receptor subunit beta-1, K(VCA)beta-1, Maxi K channel subunit beta-1, Slo-beta-1, Slo-beta, KCNMB1 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | KCNMB1 |
|---|---|
| Function | Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Increases the apparent Ca(2+)/voltage sensitivity of the KCNMA1 channel. It also modifies KCNMA1 channel kinetics and alters its pharmacological properties. It slows down the activation and the deactivation kinetics of the channel. Acts as a negative regulator of smooth muscle contraction by enhancing the calcium sensitivity to KCNMA1. Its presence is also a requirement for internal binding of the KCNMA1 channel opener dehydrosoyasaponin I (DHS-1) triterpene glycoside and for external binding of the agonist hormone 17-beta-estradiol (E2). Increases the binding activity of charybdotoxin (CTX) toxin to KCNMA1 peptide blocker by increasing the CTX association rate and decreasing the dissociation rate. |
| Cellular Location | Membrane; Multi-pass membrane protein. |
| Tissue Location | Abundantly expressed in smooth muscle. Low levels of expression in most other tissues. Within the brain, relatively high levels found in hippocampus and corpus callosum |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
MaxiK channels are large conductance, voltage andcalcium-sensitive potassium channels which are fundamental to thecontrol of smooth muscle tone and neuronal excitability. MaxiKchannels can be formed by 2 subunits: the pore-forming alphasubunit and the product of this gene, the modulatory beta subunit.Intracellular calcium regulates the physical association betweenthe alpha and beta subunits.
References
Bailey, S.D., et al. Diabetes Care (2010) In press :Xie, M.J., et al. Am. J. Physiol., Cell Physiol. 298 (6), C1489-C1500 (2010) :Yokoyama, K., et al. Nephron Clin Pract 115 (4), C237-C243 (2010) :Long, X., et al. J. Biol. Chem. 284(48):33671-33682(2009)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
